Ibrutinib 420 mg + Ibrutinib 560 mg
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Leukemia, Lymphocytic, Chronic, B-Cell
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell
Trial Timeline
Jun 26, 2019 → May 3, 2023
NCT ID
NCT03190330About Ibrutinib 420 mg + Ibrutinib 560 mg
Ibrutinib 420 mg + Ibrutinib 560 mg is a approved stage product being developed by Johnson & Johnson for Leukemia, Lymphocytic, Chronic, B-Cell. The current trial status is completed. This product is registered under clinical trial identifier NCT03190330. Target conditions include Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell.
What happened to similar drugs?
20 of 20 similar drugs in Leukemia, Lymphocytic, Chronic, B-Cell were approved
Approved (20) Terminated (2) Active (0)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03190330 | Approved | Completed |
Competing Products
20 competing products in Leukemia, Lymphocytic, Chronic, B-Cell